Showing all entries tagged with »medicines«
August 24, 2023
In this article, Michael N. Abrams and Alexander Natz discuss the current policy initiatives from Europe and the U.S., similarities between them, and implications for the pharmaceutical sector and their standing in a competitive global market. For years, lawmakers have… read more
February 22, 2023
There is still a way to go to tackle the 95% of rare diseases without treatments and Rare Disease Day 2023 serves as an important reminder of the arduous tasks ahead required to design a brighter future for European people… read more
February 2, 2023
Every year on 4 February, millions of Europeans gather to raise awareness on how to fight against cancer through early detection, treatment and support. Now, with the growth of Advanced Diagnostics in the EU, we can facilitate earlier diagnosis of… read more
December 19, 2022
Based on current discussions by the European Commission, launch conditionalities would not account for the distinct nature of small and mid-sized companies, OMPs and ATMPs. EUCOPE’s Alexander Natz breaks down this aspect of the revision of the General Pharmaceutical Legislation… read more
October 27, 2022
In this guest blog post, Takeda’s Andre Vidal Pinheiro evaluates the value of partnerships across the medicines lifecycle and why real-world evidence (RWE) is fundamental for healthcare systems to provide better and tailored outcomes for patients. The world is moving… read more